New hope drug tested alongside standard chemo for tough breast cancers
NCT ID NCT03568422
Summary
This study is testing a new oral drug, CFI-402257, given alongside a standard weekly chemotherapy (paclitaxel) for people with advanced HER2-negative breast cancer. The first part aims to find the safest dose of the new drug combination. The second part will see if adding this new drug helps shrink tumors better than the standard chemo alone. The study is for women whose cancer has spread and who have already tried at least one other non-taxane chemotherapy.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
BCCA - Vancouver Cancer Centre
Vancouver, British Columbia, V5Z 4E6, Canada
-
Kingston Health Sciences Centre
Kingston, Ontario, K7L 2V7, Canada
-
Ottawa Hospital Research Institute
Ottawa, Ontario, K1H 8L6, Canada
-
University Health Network
Toronto, Ontario, M5G 2M9, Canada
Conditions
Explore the condition pages connected to this study.